Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.740
+0.050 (2.96%)
Aug 7, 2026, 4:00 PM EDT - Market closed

Acrivon Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-82.35-84.11-89.2-67.1-32.66-16.18
Net Income
-77.27-77.91-80.56-60.39-31.17-16.24
Earnings Per Share
-2.00-2.02-2.38-2.74-7.56-9.32
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
97.74118.58179.48127.46127.7599.6
Total Debt
2.422.713.654.644.965.63
Net Cash (Debt)
95.32115.87175.84122.81122.7993.98
Net Cash Growth
-34.77%-34.10%43.17%0.02%30.66%5836.51%
Net Cash Per Share
2.473.015.205.5629.7953.90

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-64.67-63.67-65.67-42.64-30.12-13.98
Capital Expenditures
-1.63-1.67-2.77-1.29-2.17-0.24
Free Cash Flow
-66.29-65.33-68.44-43.93-32.28-14.22
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.